Aldeyra Therapeutics, Inc.
Financials
Valuation Metrics
Aldeyra Therapeutics, Inc.'s Market Cap is $36M. At end of 2025 it was $312M. Ranked #3086 of 3,115 in US market (top 99%), #1447 of 1,472 on NASDAQ (top 98%), #263 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $36M | US#3,086/3,115 Sec#263/265 |
| Revenue | $0.00 | US#2,861/3,115 Sec#193/265 |
| Net Income | $-23M | US—/3,115 Sec—/265 |
| Total Assets | $48M | US#3,074/3,115 Sec#263/265 |
| Net Assets | $38M | US#2,867/3,115 Sec#226/265 |
| Employees | 7 | US#2,780/3,115 Sec#223/265 |
| Value | ||
| P/B | 0.94x | US#453/3,115 Sec#24/265 |
| FCF Yield | -61.64% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -60.85% | US#2,715/3,115 Sec#174/265 |
| ROA | -48.49% | US#2,981/3,115 Sec#210/265 |
| Financial Health | ||
| Debt Ratio | 25.49% | US#281/3,115 Sec#93/265 |
| Total Debt | $143447.00 | US#3,009/3,115 Sec#256/265 |
| FCF | $-22M | US#2,432/3,115 Sec#97/265 |
| Cash | $45M | US#2,610/3,115 Sec#231/265 |
| Current Ratio | 4.91x | US#476/3,115 Sec#145/265 |
| Performance | ||
| 1Y Return | -88.31% | US#3,104/3,115 Sec#260/265 |
| 1M Return | -49.32% | US#3,077/3,115 Sec#262/265 |
| From 52W High | -90.00% | US#3,097/3,115 Sec#258/265 |
| 1Y MDD | -90.03% | US#3,096/3,115 Sec#257/265 |
| Trading | ||
| Volume | 846,743 shares | US#1,591/3,115 Sec#164/265 |
| Trading Value | $483600.00 | US#3,066/3,115 Sec#260/265 |
| Per Share | ||
| EPS | $-0.38 | US—/3,115 Sec—/265 |
| BPS | $0.63 | US#2,737/3,115 Sec#212/265 |
Company Info
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.